AR069682A1 - Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) - Google Patents
Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4)Info
- Publication number
- AR069682A1 AR069682A1 ARP080105419A ARP080105419A AR069682A1 AR 069682 A1 AR069682 A1 AR 069682A1 AR P080105419 A ARP080105419 A AR P080105419A AR P080105419 A ARP080105419 A AR P080105419A AR 069682 A1 AR069682 A1 AR 069682A1
- Authority
- AR
- Argentina
- Prior art keywords
- combination
- melanoma
- alpha
- ctla4
- antibodies against
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2292—Thymosin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
El melanoma o su metástasis se trata en un paciente humano en una terapia combinada la cual incluye administrar una combinacion que trata el melanoma a un paciente humano con melanoma durante un régimen de tratamiento, incluyendo la combinacion un péptido timosina alfa y anticuerpos contra el antígeno 4 asociado con linfocitos T citotoxicos (CTLA4). Reivindicacion 2: El método de acuerdo con la reivindicacion 1 donde los anticuerpos contra CTLA4 comprenden 9H10, MDX010, 1F4, BNI3, Q01, A01, M08, 1B8, WKH203, ab9984, ab13486, ipilimumab, ticilimumab o una combinacion de los mismos. Reivindicacion 6: El método de acuerdo con la reivindicacion 1 donde dicho régimen de tratamiento comprende una pluralidad de días, dicho péptido timosina alfa comprende timosina alfa 1 (TA1), y dicha TA1 se administra a dicho paciente durante por lo menos una porcion de dicho régimen de tratamiento en una dosificacion dentro de un rango de aproximadamente 0,5-10 mg/día. Reivindicacion 16: El método de acuerdo con la reivindicacion 1, donde dicha combinacion incluye además la administracion de un agente antineoplásico alquilante, (AlkAA). Reivindicacion 17: El método de acuerdo con la reivindicacion 16 donde el agente antineoplásico alquilante (AlkAA) comprende dacarbazina (DTIC).
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1310107P | 2007-12-12 | 2007-12-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR069682A1 true AR069682A1 (es) | 2010-02-10 |
Family
ID=40755783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080105419A AR069682A1 (es) | 2007-12-12 | 2008-12-12 | Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100330093A1 (es) |
EP (1) | EP2240195A4 (es) |
JP (1) | JP2011506436A (es) |
CN (1) | CN101896190A (es) |
AR (1) | AR069682A1 (es) |
AU (1) | AU2008335840A1 (es) |
CA (1) | CA2709027A1 (es) |
WO (1) | WO2009075813A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130296223A1 (en) * | 2012-03-30 | 2013-11-07 | Sciclone Pharmaceuticals, Inc. | Use of thymosin alpha for the treatment of sepsis |
US20150079192A1 (en) * | 2012-05-21 | 2015-03-19 | Marv Enterprises, LLC | Treatment of cancer by manipulating the immune system |
TWI683667B (zh) * | 2014-10-21 | 2020-02-01 | 開曼群島商賽生製藥國際有限公司 | 用免疫刺激物治療癌症 |
US10806787B2 (en) | 2015-02-16 | 2020-10-20 | Pharma Foods International Co., Ltd. | Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof |
JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ, インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
TW201735949A (zh) | 2016-03-24 | 2017-10-16 | 千禧製藥公司 | 治療抗ctla4及抗pd-1組合治療中的胃腸道免疫相關不良事件之方法 |
CN109793891A (zh) * | 2017-11-17 | 2019-05-24 | 韩震 | 多肽化合物在制备提高治疗性抗体疗效的佐剂中的应用与组合物及其制备方法 |
IT201900016310A1 (it) * | 2019-09-13 | 2021-03-13 | Luigina Romani | Timosina alfa 1 per l’uso nella prevenzione e nel trattamento degli effetti avversi immunitari correlati agli inibitori di checkpoint immunitari. |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2604845A1 (de) * | 1976-02-07 | 1977-08-18 | Knoll Ag | Neue piperazinderivate |
EP2633866A3 (en) * | 2003-10-17 | 2013-12-18 | Novo Nordisk A/S | Combination therapy |
-
2008
- 2008-12-08 CA CA2709027A patent/CA2709027A1/en not_active Abandoned
- 2008-12-08 CN CN2008801206945A patent/CN101896190A/zh active Pending
- 2008-12-08 US US12/747,817 patent/US20100330093A1/en not_active Abandoned
- 2008-12-08 JP JP2010537941A patent/JP2011506436A/ja not_active Withdrawn
- 2008-12-08 EP EP08859253A patent/EP2240195A4/en not_active Withdrawn
- 2008-12-08 AU AU2008335840A patent/AU2008335840A1/en not_active Abandoned
- 2008-12-08 WO PCT/US2008/013480 patent/WO2009075813A1/en active Application Filing
- 2008-12-12 AR ARP080105419A patent/AR069682A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20100330093A1 (en) | 2010-12-30 |
AU2008335840A1 (en) | 2009-06-18 |
CN101896190A (zh) | 2010-11-24 |
CA2709027A1 (en) | 2009-06-18 |
JP2011506436A (ja) | 2011-03-03 |
EP2240195A1 (en) | 2010-10-20 |
EP2240195A4 (en) | 2011-12-21 |
WO2009075813A1 (en) | 2009-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR069682A1 (es) | Tratamiento de melanoma con peptidos timosina alfa en combinacion con anticuerpos contra antigeno 4 asociado con linfocitos t citotoxicos (ctla4) | |
AR054237A1 (es) | Terapia de combinacion de anticuerpo antictla4 e indolinona para el tratamiento del cancer | |
EP1504778A3 (en) | Implantable pump for the treatment of obesity | |
ECSP056076A (es) | Sistema de suministro para droga y terapia celular | |
CO4970819A1 (es) | Tratamiento de disfuncion sexual femenina en una hembra humana | |
BR0205990A (pt) | Um sistema implantável de liberação unidirecional de agentes terapêuticos para tecidos | |
DE60327843D1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
TW200637546A (en) | Combination therapy | |
AR056453A1 (es) | Composiciones con estrogeno y metodos terapeuticos para su uso | |
AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
PE20001041A1 (es) | Dispositivo de suministro de farmacos, especialmente para el suministro de progestinas y estrogenos | |
BR0109266A (pt) | Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto | |
GB2431346B (en) | A combination composition comprising paracetamol and ibuprofen | |
JP2011506436A5 (es) | ||
AR069767A1 (es) | Tratamiento del melanoma con peptidos timosina alfa en combinacion con activador de apoptosis de choque termico entineoplastico (hsaa) | |
TR200002969T2 (tr) | Farmasötik bileşim. | |
BR0213821A (pt) | Conjugados de polìmero/peptìdeo timosina alfa 1 | |
BR0213823A (pt) | Método de administração de um peptìdeo timosina alfa 1 | |
AR023185A1 (es) | Tratamiento de cancer mejorado con temozolomida | |
AR025718A1 (es) | Metodo para reducir el riesgo de cancer | |
AR069769A1 (es) | Tratamiento del melanoma con peptidos de timosina alfa en combinacion con un inhibidor de quinasas | |
ATE411051T1 (de) | Polypeptid, dessen konjugat doxorubicin enthält, und auf diesem basierende pharmazeutische zusammensetzung | |
JP2020524167A5 (es) | ||
TW200626172A (en) | Treatment of HIV infection | |
Son et al. | Expression of ATG9A and ATG9B in mouse oocytes and reproductive tissues |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |